Le Lézard
Classified in: Health
Subjects: TRI, FDA

Spectra Medical Devices - Huons Co., Ltd. Announce FDA Approval to Market Bupivacaine HCL in Dextrose USP, 0.75% / 8.25% 2 mL Glass Ampules


WILMINGTON, Massachusetts, Jan. 13, 2020 /PRNewswire/ -- Spectra Medical Devices - Huons Co., Ltd. are proud to announce the FDA approval of their Abbreviated New Drug Application (ANDA) for Bupivacaine HCl with Dextrose USP, 0.75% / 8.25% in 2 mL ampules.   The product is now available along with previously approved ANDA's for Lidocaine HCl Injection, USP, 5mL ampules and Sodium Chloride Injection USP, 0.9% in 5ml and 10ml ampules. "With this FDA approval, we are now able to meet the United States demand for Bupivacaine, which currently is in limited supply nationally. Supplying Bupivacaine with Dextrose in ampules to health care providers, a product which has not been readily available, along with the largest range of custom procedural needles, is significant news for physicians and Spectra," noted Tony Arrigo, President & CEO of Spectra Medical Devices.

Spectra Logo

Spectra Medical Devices is one of the largest procedural needle manufacturers in the world, with substantial market share in over 20 countries. Spectra utilizes the latest state-of-the-art manufacturing and inspection systems, along with over 225 years of experience in manufacturing needles. Spectra operates 5 manufacturing plants worldwide with 300 employees. Corporate headquarters are located in Wilmington, Massachusetts. Spectra Medical Devices, Inc. was founded in 1995 by Tony Arrigo and is celebrating its 25th Anniversary. Mr. Arrigo was previously President & CEO and owner of American Medical Instruments, Inc. in Massachusetts which is now the needle division of Tegra Medical. Spectra has been granted several US patents for specialized needle processing and products.

Spectra Medical's primary focus is on patient safety, achieving substantial growth through quality and innovation.

To order Bupivacaine 0.75% in Dextrose in 2 mL ampules, contact Anthony Arrigo, Director, Global Sales & Marketing at [email protected]  (978) 657-0889 ext. 5231.

Contact:  
Peggy Rose Public Relations
[email protected] 
+1-617-477-9802

SOURCE Spectra Medical Devices, Inc.


These press releases may also interest you

at 20:40
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

at 19:40
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...

at 19:05
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...

at 19:00
David J. Dykeman, co-chair of the Life Sciences & Medical...

at 18:30
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community.  Aspire Health experienced a data security incident that may have involved personal and...

at 17:21
Chemistree Technology Inc. (US OTC: CHMJF) (the "Company" or "Chemistree"), is pleased to announce that the adjourned extraordinary meeting of the holders of the 10% senior unsecured convertible debentures of the Company (the "Debentures") was...



News published on and distributed by: